Investment Analysis 12 February 2026 - 3 March 2026

Viavi Solutions (VIAV) stock steadies premarket after 19% jump; Needham target hike keeps traders watching
···

Viavi Solutions (VIAV) stock steadies premarket after 19% jump; Needham target hike keeps traders watching

Viavi Solutions shares held steady Tuesday premarket after surging 19% Monday to $35.35, following a Needham price-target hike to $36 and company updates on data-center and 6G wireless testing. Insider filings showed two executives sold shares after the rally. Viavi plans to showcase new AI networking technologies at the OFC 2026 event in Los Angeles later this month.
March 3, 2026
Hims & Hers stock in focus before open after weak Q1 outlook and BTIG downgrade
···

Hims & Hers stock in focus before open after weak Q1 outlook and BTIG downgrade

Hims & Hers Health shares fell 0.5% to $15.46 in late trading Tuesday after BTIG downgraded the stock to “neutral,” citing regulatory risks and slowing growth. The company faces scrutiny over compounded weight-loss drugs and a potential Department of Justice probe. First-quarter revenue guidance missed analyst expectations, triggering a 7% after-hours drop Monday.
February 25, 2026
Halma share price hits new 52-week high near 3,900p — what’s driving HLMA stock now?
···

Halma share price hits new 52-week high near 3,900p — what’s driving HLMA stock now?

Halma shares hit a 52-week high of 3,900p in early London trade Monday, up 0.1% at 3,880p by 10:04 GMT. The FTSE 100 group has climbed 32% over the past year despite no recent company news, with traders awaiting a March 12 trading update. The stock opened at 3,872p, trading 112,700 shares by 10:05. Halma last announced an acquisition in January and posted upgraded guidance in September.
February 16, 2026
ICON (ICLR) stock rebounds after accounting probe shock — what investors watch next
···

ICON (ICLR) stock rebounds after accounting probe shock — what investors watch next

ICON shares jumped 16% in after-hours trading Friday, recovering some losses after a 40% plunge tied to an internal accounting probe and delayed earnings. The company withdrew 2025 guidance and postponed results to late April as it reviews revenue recognition for 2023–2025. Analysts at Leerink and BofA downgraded the stock and slashed price targets. ICON expects to report material weaknesses in internal controls.
February 14, 2026
Waters Corporation stock drops again as analysts reset targets after BD deal
···

Waters Corporation stock drops again as analysts reset targets after BD deal

Waters Corp shares fell 2.8% to $320 in late New York trading Thursday, extending losses after a weak first-quarter profit outlook and broker price target cuts. Wells Fargo, BofA, UBS, and TD Cowen all lowered targets, citing integration risks with BD’s biosciences and diagnostics units. Waters completed the $18.8 billion BD deal this week, with BD shareholders now owning 39.2% of the combined company.
February 12, 2026